A304360 Stock Overview
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
S.Biomedics Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩22,700.00 |
52 Week High | ₩51,600.00 |
52 Week Low | ₩7,150.00 |
Beta | 0 |
11 Month Change | -29.50% |
3 Month Change | -12.02% |
1 Year Change | 198.68% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 20.55% |
Recent News & Updates
Shareholder Returns
A304360 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 14.6% | -8.1% | 2.9% |
1Y | 198.7% | 18.1% | -2.8% |
Return vs Industry: A304360 exceeded the KR Biotechs industry which returned 21.1% over the past year.
Return vs Market: A304360 exceeded the KR Market which returned -4% over the past year.
Price Volatility
A304360 volatility | |
---|---|
A304360 Average Weekly Movement | 19.5% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 5.6% |
10% most volatile stocks in KR Market | 11.5% |
10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A304360's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A304360's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 52 | n/a | www.sbiomedics.com |
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration; CF-TED-N for the treatment of stroke; and CF-FECS-DF for the treatment of wound. The company provides testing services; and owns platform technologies for developing cell therapy products.
S.Biomedics Co., Ltd. Fundamentals Summary
A304360 fundamental statistics | |
---|---|
Market cap | ₩266.63b |
Earnings (TTM) | -₩9.77b |
Revenue (TTM) | ₩11.90b |
22.4x
P/S Ratio-27.3x
P/E RatioIs A304360 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A304360 income statement (TTM) | |
---|---|
Revenue | ₩11.90b |
Cost of Revenue | ₩5.99b |
Gross Profit | ₩5.91b |
Other Expenses | ₩15.69b |
Earnings | -₩9.77b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -831.89 |
Gross Margin | 49.70% |
Net Profit Margin | -82.10% |
Debt/Equity Ratio | 120.3% |
How did A304360 perform over the long term?
See historical performance and comparison